查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840716

犬異位性皮膚炎市場（依治療類型、產品類型、通路和形式類型）－2025-2032 年全球預測

Canine Atopic Dermatitis Market by Treatment Type, Product Type, Distribution Channel, Form Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，犬異位性皮膚炎市場將成長 33 億美元，複合年成長率為 8.67%。

主要市場統計數據
基準年2024年 16.9億美元
預計2025年 18.4億美元
預測年份：2032年 33億美元
複合年成長率（%） 8.67%

我們為相關人員準備了一份簡潔的介紹，概述了犬異位性皮膚炎的臨床複雜性、未滿足的需求和策略緊迫性。

犬異位性皮膚炎是免疫學、慢性病管理和不斷發展的治療方案的複雜交叉領域，需要製造商、臨床醫生和經銷商進行仔細的戰略考慮。異位性皮膚炎的多因子特性導致治療方法迅速多樣化，包括生物目標、全身性抗發炎藥物、補充營養保健品和緩解症狀的外用藥物。隨著相關人員重新評估其優先事項，臨床療效、安全性和犬主偏好已成為影響其商業化和臨床應用的關鍵因素。

同時，獸藥治療的監管和報銷環境也變得更加微妙，對臨床證據和上市後安全監測的審查也更加嚴格。這種轉變使得嚴謹的研究設計、真實世界證據收集和主動藥物安全檢測的重要性日益凸顯。因此，企業必須比以往更加緊密地協調臨床開發、生產品質和市場投放計劃。本執行摘要的其餘部分總結了最重要的趨勢，提供了細分市場和區域考量，分析了2025年美國關稅的影響，並為尋求永續競爭優勢的市場參與企業提出了優先且可行的建議。

治療創新、監管壓力和飼主期望的變革正在推動犬皮膚病治療途徑的重新定義

受科技進步、飼主期望變化以及整個供應鏈營運壓力的推動，犬異位性皮膚炎的治療方法正在經歷重大變革。分子生物學和免疫學領域的突破，使生物製藥（尤其是單株抗體）從實驗性療法提升為切實可行的治療方法，能夠提供針對性的緩解，並具有良好的安全性。同時，犬主擴大尋求將處方療法與營養補充劑和差異化局部護理相結合的綜合護理途徑，這為橫跨臨床和健康類別的混合產品策略創造了空間。

不斷變化的法規和付款人行為也在改變商業性模式。監管機構強調，對於仿單標示外人體應用，需要強力的證據包和清晰的標籤，並鼓勵申辦方儘早投資於對照試驗和長期安全監測。在商業方面，全通路分銷和遠端醫療正在重塑醫療管道，使專科診所和線上零售商能夠與傳統獸醫診所共存。技術支援的依從性工具和數位化互動策略正在提高飼主的依從性，並提供更豐富的真實世界資料集，以支援產品差異化。這些轉變正在加速產品生命週期決策，提升策略夥伴關係關係的重要性，並需要能夠回應臨床和市場主導需求的敏捷營運模式。

評估 2025 年美國宣布的關稅對獸醫皮膚病藥物投入和定價的累積營運和供應鏈影響

美國宣布的2025年關稅，為採購用於皮膚病治療的原料、成品和特殊零件的公司帶來了重要的考量。在整個價值鏈中，進口關稅和相關的管理成本增加了某些活性原料藥、輔料和包裝材料的到岸成本。這促使許多公司重新審視庫存策略，增加關鍵原料的安全庫存，並重新評估前置作業時間，以降低與關稅相關的波動風險。

採購團隊已採取應對措施，加快供應商多元化步伐，優先考慮近岸外包和區域供應商，以縮短物流路線並減少對關稅的依賴。雖然這些措施提高了韌性，但也引發了供應品質、監管合規性和成本競爭力方面的問題。由於製造商需要在需求下降的風險與將部分成本轉嫁給獸醫診所和零售通路之間取得平衡，定價策略面臨壓力。與此同時，談判能力有限的小型創新企業正在尋求合約製造外包夥伴關係和批量採購協議，以保護利潤率。

臨床開發項目正遭受二次影響。專用試劑和國際CRO服務成本的上漲，正在推動方案效率和選擇性入組策略的提升。監管提交現在需要額外的文件來證明供應鏈管理以及供應商變更後產品的一致性。總體而言，2025年的關稅格局強化了動態採購、積極主動的相關人員溝通以及基於情景的財務規劃的必要性，以保障供應的連續性並保持最終用戶的可負擔性。

細分主導的情報揭示了治療類型、產品形式、分銷管道和處方途徑如何影響商業化策略

細緻的細分框架揭示了臨床和商業層面的機會與限制。從治療類型來看，市場涵蓋生物製藥（以膳食補充劑配方為代表）、透過注射或口服片劑進行的全身性治療以及以乳膏、凝膠、洗髮精和噴霧劑等形式提供的外用藥物。治療類型的多樣性要求每個治療類別都有獨特的監管途徑、發展時間表和臨床醫生教育策略。

產品類型細分透過區分非處方箋藥和處方藥，進一步區分了市場方法，每種途徑都會影響行銷合規性、經銷夥伴和照護現場對話。分銷管道細分揭示了關鍵的上市選擇，包括線上零售商、專業寵物商店、傳統藥局以及獸醫診所和診所，每種選擇都提供不同的利潤概況、通路控制和資料收集機會。最後，劑型考量——從乳膏和凝膠到注射劑、口服片劑、洗髮精和噴霧劑——會影響配方複雜性、穩定性要求和飼主依從性動態。這些相互關聯的細分軸要求製造商將其臨床證據生成、包裝和商業化計劃與治療類型、監管環境、管道策略和產品形式的特定交集相結合，以最大限度地提高採用率和長期治療成功率。

亞太地區、歐洲、中東和非洲的區域動態和跨境考慮重塑了犬類藥物的​​取得和報銷

區域動態對治療藥物的可及性、定價和上市速度有著決定性的影響。在美洲，成熟的獸醫網路和不斷成長的寵物醫療保健支出推動了對差異化療法的強勁需求，同時監管部門也更傾向於循證核准和明確的安全性。在該地區營運的製造商通常優先考慮與專科診所建立合作夥伴關係並採用整合的分銷模式，以確保臨床醫生的認可並支持產品上市後的監測活動。

歐洲、中東和非洲地區（EMEA）的監管和報銷環境差異較大，各國的獸醫法規和進口規則各不相同，需要彈性的打入市場策略。符合當地監管標準的臨床數據和謹慎的跨境物流至關重要。製造商可以從區域經銷夥伴和本地製造中受益，以應對海關和合規挑戰。

在亞太地區，寵物擁有量的快速成長和獸醫服務的擴張為加速推廣創造了機會，尤其是在都市區對高階療法的認知度和投資更高。然而，市場准入必須考慮多樣化的法律規範、某些生技藥品不斷變化的低溫運輸，以及營養補充劑和外用藥的獨特區域偏好。在任何地區，將臨床訊息與當地獸醫執業模式和飼主的期望相結合，並根據當地限制調整供應鏈和定價策略，將決定商業性成功。

定義犬異位性皮膚炎治療生態系中成功參與者的關鍵企業行為、競爭差異化和合作模式

成功的公司憑藉專注的研發投入、靈活的生產策略和差異化的商業化模式脫穎而出。主要企業正在投入資源開發靶向生物製藥平台，推進安全性和有效性得到驗證的單株抗體候選藥物，同時開發營養補充劑系列，以提高患者用藥依從性並拓寬可及療法的範圍。這些整合的產品組合支援分級交付，以滿足臨床需求和所有者的偏好。

策略夥伴關係十分常見，企業與臨床研究機構、契約製造、分銷專家及其他各方攜手合作，以加速研發進度並確保產能。重視全通路分銷（包括數位優先互動工具和遠距遠端醫療診斷支援）的企業正在改善業主教育和依從性追蹤。此外，創新者正在投資上市後證據收集，以證實長期安全聲明並支持產品標籤擴展。最佳化供應鏈冗餘、建立區域製造節點並維護透明品質系統的企業正在縮短供貨時間並增強與獸醫專業人士的信任。最終，企業的成功取決於將科學差異化與切合實際的商業執行和彈性運作相結合。

為產業領導者提供優先的戰術性和策略槓桿的可行建議，以加速採用、最佳化供應鏈並加強市場進入

產業領導者應採取多管齊下的策略，在短期商業利益與中期平台建設之間取得平衡。首先，優先為差異化治療方法獲取臨床證據，重點關注對臨床醫生和藥物持有者至關重要的終點，例如持久緩解瘙癢、現實世界安全性以及改善生活品質指標。投資於務實的臨床試驗和嚴格的核准後監測，將增強臨床醫師的信心，並為產品說明書的完善提供機會。

其次，實現採購多元化，並調整供應鏈架構，以緩解關稅和物流波動。與區域供應商建立關係，認證多家製造外包，並透過與分銷夥伴更緊密的合作來改善需求預測，可以降低關稅帶來的成本衝擊。第三，推行全通路市場推廣模式，將獸醫教育、飼主的數位互動以及與精選零售商的合作結合。依照產品的監管狀態客製化通訊。非處方藥的宣傳應強調安全、常規使用，處方藥宣傳活動應以臨床有效性和獸醫指導為中心。

第四，利用策略聯盟，充分利用互補能力，例如檢測方法開發、依從性技術和在地化監管支援。最後，將定價策略與已證實的價值相結合，同時準備戰術性返利，並與大型獸醫網路進行戰術性的合約試點。這些行動要充分考慮競爭格局，才能鞏固您的市場准入之路，提高您應對宏觀環境波動的韌性，並在競爭格局中打造永續的差異化優勢。

透明的調查方法詳細說明了混合方法、資料檢驗過程以及構成分析和建議基礎的限制。

本執行摘要的分析採用了混合方法，結合了初步定性訪談、結構化二次研究以及跨多個資料流的三角檢驗，以確保獲得可靠且可操作的見解。主要輸入包括對全科和皮膚科專科診所的執業獸醫、製造和分銷機構的採購和營運負責人以及治療創新公司的業務發展主管的深入訪談。這些訪談提供了關於臨床優先事項、供應鏈漏洞和通路經濟效益的第一線觀點。

二次研究包括同行評審的犬皮膚病病理學和治療效果文獻、監管指南文件、公開的公司文件以及臨床試驗註冊。本研究對不同資訊來源的數據進行了交叉檢驗，以確定一致的主題並協調不同的發現。透過情境建模，進一步增強了方法的嚴謹性，以檢驗營運和定價結果對關稅相關中斷和供應鏈延遲的敏感度。在存在不確定性的情況下，分析強調風險調整後的建議和假設的透明度，以支持明智的決策。

總結性結論提煉了策略要點、風險考量以及相關人員在犬皮膚病學不斷發展的領域中應採取的後續步驟。

犬異位性皮膚炎的不斷發展既帶來了策略挑戰，也帶來了實際的機會。標靶治療的進步和依證的日益成熟，為臨床差異化開闢了新的途徑，而飼主行為和分銷模式的轉變也拓展了市場管道。同時，關稅和供應鏈複雜性等宏觀動態要求我們保持營運警覺並制定靈活的策略規劃。

整合嚴謹的臨床開發、彈性的供應鏈設計和全通路商業化的相關人員最有可能獲得新的價值。關鍵挑戰包括：取得臨床相關證據、投資多元化採購和生產，以及根據已證實的治療價值調整定價和存取策略。透過優先考慮這些領域並遵循切實可行的建議，企業能夠克服當前的困境，為犬皮膚病學領域的成長和治療領導地位奠定持久的基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大採用生物目標療法進行治療
  • 擴展獸醫遠端皮膚病學平台，用於遠端監測異位性皮膚病
  • 增加基於微生物組的局部治療以恢復犬的皮膚屏障功能
  • 個人化營養補充品的成長旨在支持過敏犬的免疫反應
  • 開發植物來源的植物化學配方，用於天然緩解狗的過敏
  • 整合穿戴式感測器技術即時追蹤狗的皮膚炎發展
  • 以訂閱為基礎的預防保健套餐的出現，重點關注狗狗的長期皮膚健康
  • 新型療法的監管核准趨勢和不斷變化的專利格局

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 犬異位性皮膚炎市場（依治療類型）

  • 生物製藥
    • 單株抗體
  • 營養補充品
    • 補充
  • 全身性治療
    • 注射
    • 口服錠劑
  • 外用藥物
    • 乳霜和凝膠
    • 洗髮精
    • 噴

9. 犬異位性皮膚炎市場（依產品類型）

  • 非處方藥
  • 處方箋

第 10 章犬異位性皮膚炎市場（依分銷管道）

  • 網路零售
  • 寵物專賣店
  • 藥局
  • 獸醫診所

第 11 章犬異位性皮膚炎市場（依形式類型）

  • 乳霜和凝膠
  • 注射
  • 口服錠劑
  • 洗髮精
  • 噴

第12章犬異位性皮膚炎市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章犬異位性皮膚炎市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 犬異位性皮膚炎市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Boehringer Ingelheim International GmbH
    • Merck Sharp & Dohme Corp.
    • Hill's Pet Nutrition, Inc.
    • Virbac SA
    • Ceva Sante Animale SA
    • Dechra Pharmaceuticals plc
    • Vetoquinol SA
    • Royal Canin SAS
Product Code: MRR-A339DAEFA20E

The Canine Atopic Dermatitis Market is projected to grow by USD 3.30 billion at a CAGR of 8.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.69 billion
Estimated Year [2025] USD 1.84 billion
Forecast Year [2032] USD 3.30 billion
CAGR (%) 8.67%

A concise introduction outlining the clinical complexity, unmet needs, and strategic urgency shaping the canine atopic dermatitis landscape for stakeholders

Canine atopic dermatitis presents a complex intersection of immunology, chronic care management, and evolving treatment options that demand careful strategic consideration from manufacturers, clinicians, and distributors. The condition's multifactorial nature has driven rapid diversification of therapeutic approaches, spanning targeted biological agents, systemic anti-inflammatory regimens, adjunctive nutraceuticals, and symptom-relief topical formulations. As stakeholders reassess priorities, clinical efficacy, safety profiles, and owner preferences are emerging as the dominant axes shaping commercialization and clinical adoption.

In parallel, the regulatory and reimbursement environment for veterinary therapeutics is becoming more nuanced, with increased scrutiny on clinical evidence and post-market safety monitoring. This shift amplifies the importance of rigorous trial design, real-world evidence collection, and proactive pharmacovigilance. Consequently, companies must coordinate clinical development, manufacturing quality, and go-to-market planning more tightly than in prior cycles. The remainder of this executive summary synthesizes the most consequential trends, presents segmentation and regional insights, examines 2025 tariff implications in the United States, and concludes with prioritized, actionable recommendations for market participants seeking sustained competitive advantage.

Transformative shifts in therapeutic innovation, regulatory pressures, and pet owner expectations driving a redefinition of treatment pathways in canine dermatology

The therapeutic landscape for canine atopic dermatitis is undergoing transformative change driven by scientific advances, shifting pet owner expectations, and operational pressures across supply chains. Breakthroughs in molecular biology and immunology have elevated biologics, particularly monoclonal antibodies, from experimental options to practical therapies that deliver targeted relief with favorable safety profiles. Simultaneously, owners increasingly demand integrated care pathways that combine prescription therapies with nutraceutical support and differentiated topical care, creating space for hybrid product strategies that straddle clinical and wellness categories.

Regulatory evolution and payer behavior are also altering commercial calculus. Regulators are emphasizing robust evidence packages and clearer labeling on off-label human drug adaptations, prompting sponsors to invest earlier in controlled studies and long-term safety monitoring. On the commercial front, omnichannel distribution and telemedicine are reshaping access, allowing specialty clinics and online retailers to coexist with traditional veterinary practices. Technology-enabled adherence tools and digital engagement strategies are enhancing owner compliance and enabling richer real-world datasets to support product differentiation. Together, these shifts are accelerating product lifecycle decisions, elevating the importance of strategic partnerships, and requiring nimble operating models that can respond to both clinical and market-driven imperatives.

Assessing the cumulative operational and supply chain effects of United States tariff measures announced in 2025 on veterinary dermatology inputs and pricing dynamics

Tariff measures announced in the United States in 2025 have introduced a material set of considerations for companies sourcing raw materials, finished goods, and specialized components for dermatologic therapies. Across the value chain, import duties and related administrative costs have increased landed costs for certain active pharmaceutical ingredients, excipients, and packaging supplies. This has led to a recalibration of inventory strategies, with many firms extending safety stocks for critical inputs and re-evaluating lead times to mitigate exposure to customs-related variability.

Procurement teams have responded by accelerating supplier diversification efforts, prioritizing nearshoring and regional suppliers to shorten logistical pathways and reduce tariff dependency. While these efforts can enhance resilience, they also raise questions about supply quality, regulatory alignment, and cost competitiveness. Pricing strategies have faced pressure, as manufacturers weigh partial cost pass-through to veterinary clinics and retail channels against the risk of dampening demand. In parallel, smaller innovators with limited negotiating leverage have explored contract manufacturing partnerships and bundled sourcing agreements to preserve margins.

Clinical development programs have felt secondary effects; increased costs for specialized reagents and international CRO services have prompted tighter protocol efficiency and selective enrollment strategies. Regulatory dossiers have required additional documentation to demonstrate supply chain controls and product consistency when supplier changes occur. Overall, the 2025 tariff landscape has reinforced the need for dynamic sourcing, proactive stakeholder communication, and scenario-based financial planning to protect continuity of supply and maintain affordability for end users.

Segment-driven intelligence revealing how treatment types, product forms, distribution channels, and prescription pathways converge to inform commercialization strategies

A nuanced segmentation framework illuminates opportunities and constraints across both clinical and commercial dimensions. When viewed through the lens of treatment type, the market spans biologics-where monoclonal antibodies represent a focal innovation vector-nutraceuticals typified by supplemental formulations, systemic therapies delivered via injections and oral tablets, and topicals available as creams and gels, shampoos, and sprays. This treatment-type diversity mandates distinct regulatory pathways, development timelines, and clinician education strategies for each therapeutic category.

Product-type segmentation further differentiates market approaches by delineating OTC options from prescription-only therapies, with each pathway shaping marketing compliance, distribution partnerships, and point-of-care conversations. Distribution channel segmentation highlights critical go-to-market choices across online retail, pet specialty stores, traditional pharmacies, and veterinary hospitals and clinics, each offering different margin profiles, channel controls, and data capture opportunities. Finally, form-type considerations-ranging from creams and gels to injections, oral tablets, shampoos, and sprays-affect formulation complexity, stability requirements, and owner adherence dynamics. Taken together, these interlocking segmentation axes demand that manufacturers tailor clinical evidence generation, packaging, and commercialization plans to the specific intersection of treatment type, regulatory status, channel strategy, and product form to maximize adoption and long-term therapeutic success.

Regional dynamics and cross-border considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that are reshaping access and reimbursement for canine therapies

Regional dynamics exert a decisive influence on access, pricing, and the speed of therapeutic adoption. In the Americas, well-established veterinary care networks and growing pet healthcare spend are driving strong demand for differentiated therapies, while regulatory expectations favor evidence-based approvals and clear safety profiles. Manufacturers operating in this region often prioritize partnerships with specialty clinics and integrated distribution models to ensure clinician buy-in and to support post-launch surveillance initiatives.

The Europe, Middle East & Africa region presents a heterogeneous regulatory and reimbursement environment where country-level variations in veterinary regulation and import rules require flexible market entry strategies. Here, clinical data that aligns with local regulatory standards and careful navigation of cross-border logistics are essential. Manufacturers can benefit from regional distribution partnerships and localized manufacturing arrangements to address tariff and compliance challenges.

Across Asia-Pacific, rapid pet ownership growth and expanding veterinary services are creating opportunities for accelerated uptake, particularly in urban centers where awareness and willingness to invest in premium therapies are higher. However, market entry must consider diverse regulatory frameworks, variable cold-chain infrastructure for certain biologics, and localized preferences for nutraceutical and topical solutions. In all regions, aligning clinical messaging to local veterinary practice patterns and owner expectations, while adapting supply chain and pricing strategies to regional constraints, will determine commercial success.

Key corporate behaviors, competitive differentiation, and collaboration models that define successful players in the canine atopic dermatitis therapeutic ecosystem

Successful firms are distinguishing themselves through a combination of focused R&D investment, flexible manufacturing strategies, and differentiated commercialization models. Leading companies are channeling resources into targeted biologic platforms, advancing monoclonal antibody candidates with clear safety and efficacy narratives, while simultaneously developing supportive nutraceutical lines that enhance adherence and broaden total addressable therapy bundles. These integrated portfolios enable a tiered offering that meets both clinical needs and owner preferences.

Strategic partnerships are common, with firms forming alliances across clinical research organizations, contract manufacturers, and distribution specialists to compress development timelines and secure capacity. Companies prioritizing omnichannel distribution, including digital-first engagement tools and telehealth-enabled diagnostic support, are improving owner education and adherence tracking. Additionally, innovators are investing in post-market evidence collection to substantiate long-term safety claims and to support label expansions. Operational excellence is also emerging as a competitive advantage: those that optimize supply chain redundancy, establish regional manufacturing nodes, and maintain transparent quality systems reduce time-to-supply disruptions and reinforce trust with veterinary professionals. Ultimately, corporate success hinges on aligning scientific differentiation with pragmatic commercialization execution and resilient operations.

Actionable recommendations offering prioritized tactical and strategic moves for industry leaders to accelerate adoption, optimize supply chains, and strengthen market access

Industry leaders should adopt a multi-pronged strategy that balances near-term commercialization wins with medium-term platform building. First, prioritize clinical evidence generation for differentiated therapies, focusing on endpoints that matter to clinicians and owners such as sustained pruritus reduction, safety in real-world settings, and improvement in quality-of-life metrics. Investing in pragmatic trials and robust post-approval surveillance will accelerate clinician confidence and support label-strengthening opportunities.

Second, diversify sourcing and adapt supply chain architecture to mitigate tariff and logistics volatility. Establishing regional supplier relationships, qualifying multiple contract manufacturers, and improving demand forecasting through closer collaboration with distribution partners will reduce vulnerability to tariff-induced cost shocks. Third, pursue omnichannel go-to-market models that combine veterinary clinic education, digital engagement for owners, and selective retail partnerships. Tailor messaging to the product's regulatory status-OTC communications should emphasize safe, everyday use while prescription campaigns must center on clinical efficacy and veterinarian guidance.

Fourth, leverage strategic alliances to access complementary capabilities, including assay development, adherence technologies, and localized regulatory support. Finally, align pricing strategies with demonstrated value while preparing tactical rebates or value-based contracting pilots with large veterinary networks. Collectively, these actions will strengthen market access pathways, improve resilience against macro disruptions, and create durable differentiation in a competitive landscape.

Transparent research methodology detailing the mixed-methods approach, data validation processes, and limitations underpinning the analysis and recommendations

The analysis underpinning this executive summary employed a mixed-methods approach combining primary qualitative interviews, structured secondary research, and triangulation across multiple data streams to ensure robust, actionable insights. Primary inputs included in-depth interviews with practicing veterinarians across general practice and dermatology specialty clinics, procurement and operations leaders within manufacturing and distribution organizations, and business development executives from therapeutic innovators. These interviews provided first-line perspectives on clinical priorities, supply chain vulnerabilities, and channel economics.

Secondary research encompassed peer-reviewed literature on canine dermatologic pathophysiology and treatment efficacy, regulatory guidance documents, and publicly available corporate filings and clinical trial registries. Data points from different sources were cross-validated to identify consistent themes and to reconcile divergent findings. Methodological rigor was further enhanced by scenario modeling to test the sensitivity of operational and pricing outcomes to tariff-related disruptions and supply chain delays. Limitations include the inherent variability in regional regulatory regimes and the evolving evidence base for newer therapeutic classes; where uncertainties existed, the analysis emphasized risk-adjusted recommendations and transparency about assumptions to support informed decision-making.

Concluding synthesis that distills strategic imperatives, risk considerations, and next steps for stakeholders navigating the evolving canine dermatology landscape

The evolving canine atopic dermatitis environment presents both strategic challenges and tangible opportunities. Advances in targeted therapies and a maturing evidence base are creating new pathways for clinical differentiation, while shifts in owner behavior and distribution models are expanding routes to market. At the same time, macro-level dynamics such as tariff actions and supply chain complexity necessitate heightened operational vigilance and flexible strategic planning.

Stakeholders that integrate rigorous clinical development with resilient supply chain design and omnichannel commercialization will be best positioned to capture emerging value. Key imperatives include generating clinically relevant evidence, investing in diversified sourcing and manufacturing, and aligning pricing and access strategies with demonstrated therapeutic value. By prioritizing these areas and following the actionable recommendations outlined, organizations can navigate current headwinds and establish a durable foundation for growth and therapeutic leadership in canine dermatology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of targeted biologic therapies for canine atopic dermatitis management
  • 5.2. Expansion of veterinary teledermatology platforms for remote atopic skin condition monitoring
  • 5.3. Increasing availability of microbiome-based topical treatments to restore canine skin barrier function
  • 5.4. Growth of personalized nutritional supplements designed to support immune responses in atopic dogs
  • 5.5. Development of plant-derived phytochemical formulations for natural canine allergy relief
  • 5.6. Integration of wearable sensor technology for real-time tracking of canine dermatitis flare ups
  • 5.7. Emergence of subscription-based preventative care packages focused on long-term skin health in dogs
  • 5.8. Regulatory approval trends and patent landscape evolution for novel canine atopic dermatitis therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Atopic Dermatitis Market, by Treatment Type

  • 8.1. Biologics
    • 8.1.1. Monoclonal Antibodies
  • 8.2. Nutraceuticals
    • 8.2.1. Supplements
  • 8.3. Systemic Therapies
    • 8.3.1. Injections
    • 8.3.2. Oral Tablets
  • 8.4. Topicals
    • 8.4.1. Creams & Gels
    • 8.4.2. Shampoo
    • 8.4.3. Sprays

9. Canine Atopic Dermatitis Market, by Product Type

  • 9.1. Otc
  • 9.2. Prescription

10. Canine Atopic Dermatitis Market, by Distribution Channel

  • 10.1. Online Retail
  • 10.2. Pet Specialty Stores
  • 10.3. Pharmacies
  • 10.4. Veterinary Hospitals Clinics

11. Canine Atopic Dermatitis Market, by Form Type

  • 11.1. Creams & Gels
  • 11.2. Injections
  • 11.3. Oral Tablets
  • 11.4. Shampoo
  • 11.5. Sprays

12. Canine Atopic Dermatitis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Canine Atopic Dermatitis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Canine Atopic Dermatitis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Elanco Animal Health Incorporated
    • 15.3.3. Boehringer Ingelheim International GmbH
    • 15.3.4. Merck Sharp & Dohme Corp.
    • 15.3.5. Hill's Pet Nutrition, Inc.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Ceva Sante Animale S.A.
    • 15.3.8. Dechra Pharmaceuticals plc
    • 15.3.9. Vetoquinol S.A.
    • 15.3.10. Royal Canin S.A.S.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANINE ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANINE ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANINE ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY D